| NCT ID | NCT03809585 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oregon Health and Science University |
| Condition | Iris Tumor |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2018-06-20 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2018-06-20 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an observational study using OCT angiography to assist with tumor characterization in melanotic and amelanotic iris lesions. OCT angiography data from healthy eyes will be compared to eyes with various types of iris tumors.
Eligibility Criteria
Inclusion Criteria for tumor group: * Eyes with diagnosis of melanotic or amelanotic iris tumors Inclusion Criteria for healthy control group: * Eyes without iris defects or lesions Exclusion Criteria (both groups): * Inability to give informed consent * Inability to maintain stable fixation for OCT imaging * Inability to commit to required study visits * Eyes with concurrent retinal diseases, glaucoma, or conditions that in the opinion of the investigators might affect iris circulation * Mature cataracts if found to limit visual potential to worse than 20/40
Contact & Investigator
David Huang, MD, PhD
PRINCIPAL INVESTIGATOR
Oregon Health and Science University
Frequently Asked Questions
Who can join the NCT03809585 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Iris Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03809585 currently recruiting?
Yes, NCT03809585 is actively recruiting participants. Contact the research team at romfhd@ohsu.edu for enrollment information.
Where is the NCT03809585 trial being conducted?
This trial is being conducted at Portland, United States.
Who is sponsoring the NCT03809585 clinical trial?
NCT03809585 is sponsored by Oregon Health and Science University. The principal investigator is David Huang, MD, PhD at Oregon Health and Science University. The trial plans to enroll 100 participants.